Life Sciences Industry Veteran Todd R. Nelson Named SGI-DNA CEO to Lead Spin-out from Synthetic Genomics

SAN DIEGO, CA. July 2, 2018 — SGI-DNA, a leader in commercial DNA synthesis, today announced industry veteran Todd R. Nelson, Ph.D., MBA has been appointed Chief Executive Officer to lead the spin-out of the company from Synthetic Genomics, Inc. (SGI).

“Todd is a proven life sciences leader who brings a wealth of knowledge and experience to commercial organizations like SGI-DNA with disruptive instrument and reagent platforms, and we are very pleased to have him lead the organization during this time of accelerated growth,” said Oliver Fetzer, Ph.D., MBA, Chief Executive Officer of Synthetic Genomics and SGI-DNA Board member. “With more than 20 years industry experience and an outstanding value creation track record in prior CEO roles, Todd is poised to take SGI-DNA and its exciting platform centered around the BioXp™ System, the world’s first benchtop DNA printer, to new heights.”

Todd was previously responsible for leading several life sciences companies through expansive phases of financial and commercial growth including eBioscience (acquired by Affymetrix, now Thermo Fisher), MP Biomedicals (acquired by Valeant Fine Chemicals), and most recently, DiscoverX Corporation (now Eurofins). Todd is the founder of Tonbo Biosciences and TCRx Corporation.

“I look forward to helping SGI-DNA capitalize on its rapid phase of innovation and commercial development,” said Todd R. Nelson, Ph.D., MBA. “The company enjoys an unusual mix of successful ingredients: a highly differentiated and disruptive product line, exposure to large, rapidly growing emerging markets, great people, and great customers. I’m confident we can fully leverage critical assets and realize the businesses’ full upside potential as the global leader in integrated DNA synthesis solutions.”

About SGI-DNA

SGI-DNA is a subsidiary of Synthetic Genomics, Inc. (SGI) and commercializes genomic tools to advance scientific discovery. The company’s suite of gene synthesis instrumentation, reagents, bioinformatics, and services enable scientists to discover, design, and build novel solutions for basic research and biomedical and industrial applications. In 2014, SGI-DNA launched the BioXp™ 3200 System, the world’s first DNA printer. This fully automated genomic workstation was innovated by research and development scientists at SGI to create double-stranded DNA fragments, automated cloning, and next-generation sequencing DNA library preparation. More information about SGI-DNA and the BioXp System is available at www.sgidna.com.

About Synthetic Genomics, Inc.

Synthetic Genomics, Inc. (SGI) is a private biotechnology company harnessing the power of living cells — nature’s most efficient machines — to create transformative medicines and bio-based products. With an unmatched understanding of how DNA and RNA instruct the functions of life, we program cells for improved purpose and function. Our R&D competencies focus on our novel self-amplifying RNA replicon platform for infectious disease and oncology vaccines and therapeutics and our algal cell systems for industrial and biotherapeutic discovery and manufacturing. Built on a legacy of scientific firsts, our team of biological engineers are shaping the future bioeconomy. For more information about our research, partnering opportunities or careers, please visit us at www.syntheticgenomics.com to learn more.

Synthetic Genomics Appoints Reinhard J. Ambros, Ph.D., Former Global Head of the Novartis Venture Fund to Board of Directors

SAN DIEGO, CA — June 25, 2018 — Synthetic Genomics, Inc. (SGI), a leader in designing and programming biology for function, today announced Reinhard J. Ambros, Ph.D., has joined the company’s Board of Directors.

Dr. Ambros was the global head of the Novartis Venture Fund from 2005 to 2017 and built one of the largest and most active corporate Biotechnology Venture Funds globally. As the fund manager, he built a team of respected investment managers in Europe and the United States and led many significant venture investments and exits via M&A or IPO. He has a broad network with key finance syndicate partners and pharma organizations.

“I am honored to welcome Reinhard to our Board as part of an ongoing effort to strengthen the composition of our team and ensure we have the right mix of skills and expertise to lead us forward,” said Oliver Fetzer, Ph.D., MBA, Chief Executive Officer at Synthetic Genomics. “Reinhard has exceptional business development and pharmaceutical drug development experience that will help us further progress our leading-edge cell engineering platforms.”

Prior to the Novartis Venture Fund, Dr. Ambros was head of Group Strategic Planning for Novartis AG and led business development and licensing in the cardiovascular and metabolic disease area for Novartis Pharma AG. Earlier in his career he led pharmaceutical product development projects in various therapeutic areas for Novartis Pharma AG and Hoffmann-La Roche.

Dr. Ambros is the independent lead director of the Board of Directors of Aileron Therapeutics, Cambridge, MA, and is a board member for some European biotech companies. He also serves as advisor to the German Government´s (BMBF) Go-Bio Fund. Dr. Ambros received a Ph.D. from the University of Regensburg, Germany.

“I’m excited to join the Board of Synthetic Genomics and to help the company drive towards profitability and deliver on the exciting potential of the company’s transformative platform for the next-generation of medicines,” commented Dr. Ambros.

About Synthetic Genomics, Inc.

Synthetic Genomics, Inc., is a private biotechnology company harnessing the power of living cells — nature’s most efficient machines — to create transformative medicines and bio-based products. With an unmatched understanding of how DNA and RNA instruct the functions of life, we program cells for improved purpose and function. Our R&D competencies focus on our novel self-amplifying RNA replicon platform for infectious disease and oncology vaccines and our algal cell systems for industrial and biotherapeutic discovery and manufacturing. Built on a legacy of scientific firsts, our team of biological engineers are shaping the future bioeconomy. For more information about our research, partnering opportunities or careers, please visit us at www.syntheticgenomics.com to learn more.

Forward-Looking Statements

Statements in this press release that are not historical facts are forward-looking statements. In addition, we may from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. All of these forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, actual results may differ materially from those expected. We caution you against placing substantial reliance on the forward-looking statements contained in this document. All forward-looking statements included in this document are made only as of the date of this press release. We will not necessarily update any forward-looking statements as a result of new information or future events or developments.

Synthetic Genomics to Present at Upcoming Investor Conferences

Synthetic Genomics to Present at Upcoming Investor Conferences

SAN DIEGO, May 11, 2018 – Synthetic Genomics, Inc. announced today that Oliver Fetzer, Ph.D., MBA, Chief Executive Officer, will present at the upcoming Bank of America Merrill Lynch 2018 Healthcare Conference and the Jefferies 2018 Global Healthcare Conference.

Details of the presentations are as follows:

Bank of America Merrill Lynch 2018 Healthcare Conference

Date: Thursday, May 17, 2018

Time: 10:00am Pacific Time

Location: Las Vegas, Nevada

Jefferies 2018 Global Healthcare Conference

Date: Tuesday, June 5, 2018

Time: 10:00am Eastern Time

Location: New York, New York

About Synthetic Genomics, Inc.

Synthetic Genomics, Inc. is a San Diego biotechnology company harnessing the power of living cells — nature’s most efficient machines — to create transformative medicines and bio-based products. With an unmatched understanding of how DNA and RNA instruct the functions of life, Synthetic Genomics programs cells for purpose. Core R&D programs focus on self-amplifying RNA for infectious disease and oncology vaccines, automated precision medicine production, and biotherapeutic discovery and manufacturing. Built on a legacy of scientific firsts, Synthetic Genomics’ team of biological engineers are shaping the future bioeconomy. For more information about our research, partnering opportunities or careers, please visit us at www.syntheticgenomics.com to learn more.

Forward-Looking Statements

Statements in this press release that are not historical facts are forward-looking statements. In addition, we may from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. All of these forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, actual results may differ materially from those expected. We caution you against placing substantial reliance on the forward-looking statements contained in this document. All forward-looking statements included in this document are made only as of the date of this press release. We will not necessarily update any forward-looking statements as a result of new information or future events or developments.

 

ExxonMobil and Synthetic Genomics Algae Biofuels Program Targets 10,000 Barrels Per Day by 2025

  • Program advances to outdoor testing in California of naturally occurring algae strains
  • Will inform fundamental engineering necessary for scaling up technology
  • Outdoor testing phase critical step in determining path toward commercial production

Irving, TX & La Jolla, CA – March 6, 2018 – ExxonMobil and Synthetic Genomics Inc. today announced a new phase in their joint algae biofuel research program that could lead to the technical ability to produce 10,000 barrels of algae biofuel per day by 2025.

The new phase of research includes an outdoor field study that will grow naturally occurring algae in several contained ponds in California. The research will enable ExxonMobil and Synthetic Genomics to better understand fundamental engineering parameters including viscosity and flow, which cannot easily be replicated in a lab. The results of this work are important to understand how to scale the technology for potential commercial deployment.

Additional work will be required to advance larger-scale production. Both companies are continuing with fundamental research on algae biology in their laboratories as the field study advances. ExxonMobil anticipates that 10,000 barrels of algae biofuel per day could be produced by 2025 based on research conducted to date and emerging technical capability.

“Our work with Synthetic Genomics on algae biofuels continues to be an important part of our broader research into lower-emission technologies to help reduce the risk of climate change,” said Vijay Swarup, vice president for research and development at ExxonMobil Research and Engineering Company. “The new outdoor phase is a critical next step in determining a path toward large-scale, commercial production.”

This outdoor research follows the companies’ years of fundamental biological research into understanding and improving algae oil production.

“We are excited to take this next significant step as we journey together toward a renewable, scalable, and low-carbon biofuel,” said Oliver Fetzer, Ph.D., chief executive officer at Synthetic Genomics. “The progress we are making in the lab toward engineering highly efficient algae strains that convert sunlight and CO2 into renewable high energy density biofuel is exciting and warrants continued research about how our technology will scale. Our outdoor algal facility creates a perfect stepping stone from our labs to the greenhouse and to the outdoors to lay the foundation for a large scale commercial deployment of our technology in the future.”

Since 2009, ExxonMobil and Synthetic Genomics have been partners in researching and developing oil from algae to be used as a renewable, lower-emission alternative to traditional transportation fuels.

ExxonMobil is engaged in a wide range of research on advanced biofuels, partnering with universities, government laboratories, and other companies.

In 2017, ExxonMobil and Synthetic Genomics announced breakthrough research published in Nature Biotechnology that resulted in a modified algae strain that more than doubled oil content without significantly inhibiting growth, a key challenge along the path to commercial scalability.

Global demand for transportation-related energy is projected to increase by about 25 percent through 2040, and accelerating the reduction in emissions from the transportation sector will play a critical role in reducing global greenhouse gas emissions.

ExxonMobil is also actively researching other emission-reducing technologies, including carbon capture and sequestration. In 2016, ExxonMobil announced its partnership with Connecticut-based FuelCell Energy, Inc. to advance the use of carbonate fuel cells to economically capture carbon emissions from power plants while generating hydrogen and additional electricity. Since 2000, ExxonMobil has spent about $8 billion to develop and deploy lower-emission energy solutions across its operations.

About ExxonMobil

ExxonMobil, the largest publicly traded international energy company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is one of the largest refiners and marketers of petroleum products and its chemical company is one of the largest in the world. For more information, visit www.exxonmobil.com or follow us on Twitter www.twitter.com/exxonmobil.

Cautionary Statement: Statements of future events or conditions in this release are forward-looking statements. Actual future results, including the timing, results and impact of new technologies, could differ significantly depending on the outcome of further research and testing; the development and competitiveness of alternative technologies; the ability to develop and scale pilot projects on a cost-effective basis; political and regulatory developments; and other factors discussed in this release and under the heading “Factors Affecting Future Results” on the Investors page of ExxonMobil’s website at exxonmobil.com.

About Synthetic Genomics

Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind’s most pressing issues, from the wellbeing of our population to the health of our planet. With an unmatched understanding of how DNA drives the function of cells — the basic biological units of all living organisms — Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, and biotechnology research. In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in health care, energy, and other sectors. Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. More information is available at www.syntheticgenomics.com.

C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic Genomics

Los Angeles & La Jolla, CA – February 28, 2018 – C3J Therapeutics, Inc., a private biotechnology company focused on the development of novel targeted antimicrobials, and Synthetic Genomics, Inc., (SGI) a leader in designing and programming biology for desired function, announced today an agreement between the two companies to integrate SGI’s proprietary engineered bacteriophage (or phage) platform with C3J’s R&D programs addressing high unmet medical needs linked to infectious diseases.  Read more

Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

San Diego, CA – October 31, 2017 – Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. The collaboration will bring together Arcturus’s LUNAR™ lipid-mediated delivery platform with Synthetic Genomics’ RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics. Read more

Synthetic Genomics and Ceva Enter Agreement to Develop, Commercialize Next-Generation Vaccines for Animal Health

San Diego, CA – October 31, 2017 – Synthetic Genomics, Inc. announced today that the company has entered into a collaboration with Ceva Santé Animale to utilize Synthetic Genomics’ next-generation synthetic RNA replicon platform to develop vaccines for livestock. The technology opens the door to more effective vaccines and therapeutics. Read more

Synthetic Genomics Partners with Duke Human Vaccine Institute on DARPA Pandemic Prevention Platform Program

San Diego, CA — October 26, 2017 — Synthetic Genomics, Inc. is part of the recently funded DARPA Pandemic Prevention Platform (P3) program aimed at establishing a system capable of halting viral pandemics within 60 days. As part of the collaboration, led by Duke, Synthetic Genomics will contribute synthetic biology technologies to enable rapid delivery of anti-viral countermeasures. Read more

BioXp™ Genomic Workstation Makes European Debut at VIB Research Institute in Belgium

SGI-DNA’s benchtop automated DNA printer to accelerate genomic research as part of VIB’s Technology Watch Initiative

Flanders, Belgium & San Diego, CA – Aug. 22, 2017 – SGI-DNA Inc., a Synthetic Genomics Inc. (SGI) company, and VIB, a Belgian life science research institute, today announced that VIB will become the first institute in Europe to integrate the BioXp™ 3200 System in its workflows as part of its vision for adopting breakthrough technologies.  The BioXp™ 3200 System is the world’s first benchtop automated genomic workstation that rapidly prints high-quality, double-stranded DNA fragments and clones into any vector in an overnight run. With the BioXp™ 3200 System, VIB will be accelerating turnaround time for generating custom DNA for genomic research.

VIB’s Technology Watch Initiative implements new, emerging, and disruptive technologies into its laboratories and research facilities. Active since 2008, the Technology Watch program evaluates strategic technology investment opportunities and provides the funding to secure prototype instruments and early-stage technologies from high-potential fields such as Synthetic Biology, CRISPR, and single-cell analysis. The BioXp™ 3200 System will be placed in the lab of Thomas Jacobs, Ph.D., a VIB scientist in the VIB-UGent Center for Plant Systems Biology,  who is developing and optimizing plant genome editing through the use of CRISPR/Cas systems.

“The BioXp™ 3200 System will fundamentally change the way our research group approaches cloning. Not only will it greatly reduce our turnaround time for cloning projects, but also will hopefully open up new ways to test the gene editing systems we are developing,” says Dr. Jacobs.

“By automating rapid DNA synthesis, this will put VIB in a competitive position, allowing researchers to focus their time on the crucial scientific questions rather than on routine lab work,” adds Halina Novak, Ph.D., Technology Watch program manager at VIB.

Scientists are able to specifically design and clone genes with the BioXp™ System to answer key questions in their function  in biological systems. With the BioXp™ 3200 System, researchers do not need a template to obtain a gene of interest. Genes are built in silico, designed with sequence modifications to address the specific research.

“Automating gene synthesis promotes scientific discovery and advancement,” says Nathan Wood, president of SGI-DNA. “The global expansion of the BioXp™ 3200 System, notably to one of Europe’s most innovative research institutes, will help to facilitate further genomic breakthroughs in life science research.”

More information is available at sgidna.com/bxp3200.

About VIB

Basic research in life sciences is VIB’s raison d’être. VIB is pushing the boundaries of molecular mechanisms and how they rule living organisms, such as human beings, animals, plants and microorganisms, while also creating tangible results for the benefit of society. Based on a close partnership with five Flemish universities – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University – and supported by a solid funding program, VIB unites the expertise of 75 research groups in a single institute. VIB’s technology transfer activities translate research results into new economic ventures which, in time, lead to new products that can be used in medicine, agriculture and other applications. VIB also engages actively in the public debate on biotechnology by developing and disseminating a wide range of science-based information about all aspects of biotechnology. More information: www.vib.be.

VIB Tech Watch

Through the strategic application of VIB Tech Watch funds, VIB labs boast groundbreaking new technologies such as those enabling human genome sequencing, bioinformatics, next generation DNA sequencing, and a diverse range of visualization and proteomics technologies. Over the years, Tech Watch has gathered in-depth information about disruptive technologies that could aid VIB scientists, sharing over 100 of these innovations with the entire organization in the last eight years and assisting researchers in obtaining funds to use these technologies to boost research output. VIB’s partnership with SGI-DNA is only one illustration of how the VIB Technology Watch team drives cutting-edge science.

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics Inc., provides genomic solutions to advance scientific discovery. SGI-DNA’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. SGI-DNA’s genomic services include whole genome sequencing, DNA synthesis, library design, bioinformatics, cell engineering, and plasmid DNA cloning and purification. SGI-DNA’s reagents include a complete suite of Gibson Assembly® and Site Directed Mutagenesis kits as well as optimized cell lines such as Vmax™ a novel, fast growing host system for molecular biology. To further enable synthetic biology workflows, SGI-DNA offers the BioXp™ 3200 System. This fully automated genomics workstation allows the creation of double stranded DNA fragments, automated cloning, as well as Next Generation Sequencing DNA library preparation. Building on scientific breakthroughs from J. Craig Venter, Hamilton Smith, Clyde Hutchison, Daniel Gibson and their teams, SGI-DNA is committed to reducing barriers associated with synthetic biology. More information is available at sgidna.com.

About Synthetic Genomics

Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind’s most pressing issues, from the wellbeing of our population to the health of our planet. With an unmatched understanding of how DNA drives the function of cells — the basic biological units of all living organisms — Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in energy, health care and other sectors. Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. More information is available at syntheticgenomics.com.

###

Synthetic Genomics Contact:

Corporate Communications and Media
Ian Stone, Canale Communications
ian@canalecomm.com
619-849-6005

SGI-DNA Contact:

Liz Liner, Synthetic Genomics
pr@sgidna.com
858.433.2213

VIB Contact:

Halina Novak, VIB Tech Watch
halina.novak@vib.be
+32 9 244 66 11

ExxonMobil and Synthetic Genomics Report Breakthrough in Algae Biofuel Research

  • Algae strain developed and modified by Synthetic Genomics more than doubled oil production
  • Additional research and testing required before commercial application
  • Results published in peer-reviewed journal Nature Biotechnology

Irving, TX & La Jolla, CA – June 19, 2017 – ExxonMobil and Synthetic Genomics Inc. today announced a breakthrough in joint research into advanced biofuels involving the modification of an algae strain that more than doubled its oil content without significantly inhibiting the strain’s growth.

Using advanced cell engineering technologies at Synthetic Genomics, the ExxonMobil-Synthetic Genomics research team modified an algae strain to enhance the algae’s oil content from 20 percent to more than 40 percent. Results of the research were published today in the peer-reviewed journal Nature Biotechnology by lead authors Imad Ajjawi and Eric Moellering of Synthetic Genomics.

Researchers at Synthetic Genomics’ laboratory in La Jolla discovered a new process for increasing oil production by identifying a genetic switch that could be fine-tuned to regulate the conversion of carbon to oil in the algae species, Nannochloropsis gaditana. The team established a proof-of-concept approach that resulted in the algae doubling its lipid fraction of cellular carbon compared to the parent – while sustaining growth.

“This key milestone in our advanced biofuels program confirms our belief that algae can be incredibly productive as a renewable energy source with a corresponding positive contribution to our environment,” said Vijay Swarup, vice president for research and development at ExxonMobil Research and Engineering Company. “Our work with Synthetic Genomics continues to be an important part of our broader research into lower-emission technologies to reduce the risk of climate change.”

“The major inputs for phototropic algae production are sunlight and carbon dioxide, two resources that are abundant, sustainable and free,” said Oliver Fetzer, Ph.D., chief executive officer at Synthetic Genomics. “Discoveries made through our partnership with ExxonMobil demonstrate how advanced cell engineering capabilities at Synthetic Genomics can unlock biology to optimize how we use these resources and create solutions for many of today’s sustainability challenges – from renewable energy to nutrition and human health.”

Algae has been regarded as a potential sustainable fuel option, but researchers have been hindered for the past decade in developing a strain that is high in oil content and grows quickly – two critical characteristics for scalable and cost-efficient oil production. Slower growth has been an adverse effect of previous attempts to increase algae oil production volume.

A key objective of the ExxonMobil-Synthetic Genomics collaboration has been to increase the lipid content of algae while decreasing the starch and protein components without inhibiting the algae’s growth. Limiting availability of nutrients such as nitrogen is one way to increase oil production in algae, but it can also dramatically inhibit or even stop photosynthesis, stunting algae growth and ultimately the volume of oil produced.

The ability to sustain growth while increasing oil content is an important advance. Algae has other advantages over traditional biofuels because it can grow in salt water and thrive in harsh environmental conditions, therefore limiting stress on food and fresh water supplies.

Oil from algae can also potentially be processed in conventional refineries, producing fuels no different from convenient, energy-dense diesel. Oil produced from algae also holds promise as a potential feedstock for chemical manufacturing.

“The SGI-ExxonMobil science teams have made significant advances over the last several years in efforts to optimize lipid production in algae. This important publication today is evidence of this work, and we remain convinced that synthetic biology holds crucial answers to unlocking the potential of algae as a renewable energy source,” said J. Craig Venter, Ph.D., Synthetic Genomics co-founder and chairman. “We look forward to continued work with ExxonMobil so that eventually we will indeed have a viable alternative energy source.”

Since 2009, ExxonMobil and Synthetic Genomics have been partners in researching and developing oil from algae to be used as a renewable, lower-emission alternative to traditional transportation fuels. Swarup said that while the breakthrough is an important step, the technology is still many years from potentially reaching the commercial market.

“Advancements as potentially important as this require significant time and effort, as is the case with any research and development project,” Swarup said. “Each phase of our algae research, or any other similar project in the area of advanced biofuels, requires testing and analysis to confirm that we’re proceeding down a path toward scale and commercial viability.”

ExxonMobil is engaged in a wide range of research on advanced biofuels, partnering with universities, government laboratories, and other companies. Global demand for transportation-related energy is projected to increase by about 25 percent through 2040, and accelerating the reduction in emissions from the transportation sector will play a critical role in reducing global greenhouse gas emissions.

ExxonMobil is also actively researching other emission-reducing technologies, including carbon capture and sequestration. In 2016, ExxonMobil announced its partnership with Connecticut-based FuelCell Energy, Inc. to advance the use of carbonate fuel cells to economically capture carbon emissions from power plants while generating hydrogen and additional electricity. Since 2000, ExxonMobil has spent about $8 billion to develop and deploy lower-emission energy solutions across its operations.

# # #

NOTE TO EDITORS:

Vijay Swarup, Craig Venter and Oliver Fetzer will discuss the research breakthrough and answer questions during a media briefing scheduled for 10 a.m. PDT today at the San Diego Convention Center, located at 111 W. Harbor Drive, in Room 32B on the upper level. The live briefing and replay may also be accessed online via an interactive webcast.

About ExxonMobil

ExxonMobil, the largest publicly traded international energy company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is one of the largest refiners and marketers of petroleum products and its chemical company is one of the largest in the world. For more information, visit www.exxonmobil.com or follow us on Twitter www.twitter.com/exxonmobil.

Cautionary Statement: Statements of future events or conditions in this release are forward-looking statements. Actual future results, including the timing, results and impact of new technologies, could differ significantly depending on the outcome of further research and testing; the development and competitiveness of alternative technologies; the ability to develop and scale pilot projects on a cost-effective basis; political and regulatory developments; and other factors discussed in this release and under the heading “Factors Affecting Future Results” on the Investors page of ExxonMobil’s website at exxonmobil.com.

About Synthetic Genomics

Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind’s most pressing issues, from the wellbeing of our population to the health of our planet. With an unmatched understanding of how DNA drives the function of cells — the basic biological units of all living organisms — Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in health care, energy, and other sectors. Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. More information is available at www.syntheticgenomics.com.

Contact:

ExxonMobil Media Relations, 972-444-1107
Synthetic Genomics Media Relations, 619-849-6005